Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlatesAzra Ajkunic, Michael C. Haffner, Erolcan Sayar et al.|npj Precision Oncology|2024Cited by 34
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer modelsSupreet Agarwal, Kathleen Kelly, Martine P. Roudier et al.|Journal of Clinical Investigation|2023Cited by 33
Assessment of Cell Surface Targets in Metastatic Prostate Cancer: Expression Landscape and Molecular CorrelatesMichael C. Haffner, Peter S. Nelson, Azra Ajkunic et al.|Research Square|2023Cited by 4
Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancerSupreet Agarwal, Kathleen Kelly, Lei Fang et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1